ReviewThe international journal of biochemistry & cell biology2013
Muscle wasting from kidney failure-a model for catabolic conditions.
Review in The international journal of biochemistry & cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 80 citations in OpenAlex.
- Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Trial
- Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking Combined Supplementation With Curcumin And Resveratrol.Clinical interventions in aging · 2019Trial
- Trial
- Epidemiology of rehabilitation practices for inpatients with nephrotic syndrome: a retrospective cohort study using an administrative database.Clinical and experimental nephrology · 2026Article
- Anabolic and catabolic responses to different modes of exercise in patients with chronic kidney disease.BMC nephrology · 2026Observational
- Chronic Kidney Disease, Sarcopenia, and Hormonal-Metabolic Alterations: An Intriguing Association.Kidney & blood pressure research · 2026Review
- Development and multi-cohort validation of a sarcopenia-inflammation index for predicting all-cause mortality in patients with chronic kidney disease.Frontiers in nutrition · 2026Article
- Transcriptomic suppression of immune and ECM stability in skeletal muscle of patients with chronic kidney disease.PloS one · 2026Article
- Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025Review
- Efficacy of intradialytic neuromuscular electrical stimulation and oral nutritional supplementation in hemodialysis patients: a multicenter, randomized controlled trial.Kidney research and clinical practice · 2025Article
- Skeletal Muscle Injury in Chronic Kidney Disease-From Histologic Changes to Molecular Mechanisms and to Novel Therapies.International journal of molecular sciences · 2024Review
- A tryptophan-derived uremic metabolite/Ahr/Pdk4 axis governs skeletal muscle mitochondrial energetics in chronic kidney disease.JCI insight · 2024Article
- Exercise for patients with chronic kidney disease: from cells to systems to function.American journal of physiology. Renal physiology · 2024Review
- Does sodium bicarbonate based extra-cellular buffering support reduce high intensity exercise-induced fatigue and enhance short-term recovery assessed by selected blood biochemical indices?Biology of sport · 2024Article
- The Contribution of Muscle Innate Immunity to Uremic Cachexia.Nutrients · 2023Review
- Redox Signaling in Chronic Kidney Disease-Associated Cachexia.Antioxidants (Basel, Switzerland) · 2023Review
- Bacteroides plebeius improves muscle wasting in chronic kidney disease by modulating the gut-renal muscle axis.Journal of cellular and molecular medicine · 2022Article
- Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications-A Narrative Review.International journal of molecular sciences · 2022Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purposeMuscle atrophy is a frequent complication of chronic kidney disease (CKD) and is associated with increased morbidity and mortality. The processes causing loss of muscle mass are also present in several catabolic conditions. Understanding the pathogenesis of CKD-induced muscle loss could lead to therapeutic interventions that prevent muscle wasting in CKD and potentially, other catabolic conditions. MAJOR
findingsInsulin or IGF-1 resistance caused by CKD, acidosis, inflammation, glucocorticoids or cancer causes defects in insulin-stimulated intracellular signaling that suppresses IRS-1 activity leading to decreased phosphorylation of Akt (p-Akt). A low p-Akt activates caspase-3 which provides muscle proteins substrates of the ubiquitin-proteasome system (UPS). A low p-Akt also leads to decreased phosphorylation of forkhead transcription factors which enter the nucleus to stimulate the expression of atrogin-1/MAFbx and MuRF1, E3 ubiquitin ligases that can be associated with proteolysis of muscle cells by the UPS. Caspase-3 also stimulates proteasome-dependent proteolysis in muscle. SUMMARY: In CKD, diabetes, inflammatory conditions or in response to acidosis or excess glucocorticoids, insulin resistance develops, initiating reduced IRS-1/PI3K/Akt signaling. In CKD, this reduces p-Akt which stimulates muscle proteolysis by activating caspase-3 and the UPS. Second, caspase-3 cleaves actomyosin yielding substrates for the UPS and increased proteasome-mediated proteolysis. Third, p-Akt down-regulation suppresses myogenesis in CKD. Fourth, exercise in CKD stimulates insulin/IGF-1 signaling to reduce muscle atrophy. Lastly, there is evidence that microRNAs influence insulin signaling providing a potential opportunity to design therapeutic interventions. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.